Ojemda tovorafenib

Drug Class

Oral selective type II RAF kinase inhibitor

Mechanism

Selectively inhibits both monomeric and dimeric forms of RAF kinases (including BRAF V600 and BRAF fusions), blocking downstream MAPK cascade.

Approved Indication

FDA-approved for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

What This Means For Patients

Ojemda is a targeted oral RAF inhibitor developed for pediatric low-grade glioma. Approved by the FDA, it is accessible for clinical use under Hainan pilot-zone regulations.

Regulatory Approvals

• FDA — approved (2024) — source

Pivotal Clinical Evidence

• FIREFLY-1 — Kilburn et al., Nat Med 2024 (NCT04775485) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-6-months-age-and-older-relapsed-or-refractory
• https://www.dayonebio.com/investors-media/